

# Toni K Choueiri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6798379/toni-k-choueiri-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

983  
papers

57,497  
citations

107  
h-index

221  
g-index

1,099  
ext. papers

75,145  
ext. citations

6.7  
avg, IF

7.87  
L-index

#	Paper	IF	Citations
983	Integrative clinical and molecular characterization of translocation renal cell carcinoma.. <i>Cell Reports</i> , <b>2022</b> , 38, 110190	10.6	3
982	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2022</b> , 20, 71-90	7.3	20
981	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.. <i>Lancet Oncology</i> , <b>2022</b> ,	21.7	9
980	Anti-CAIX BBI-7083 T cells exhibit superior efficacy in a ccRCC mouse model.. <i>Molecular Therapy - Oncolytics</i> , <b>2022</b> , 24, 385-399	6.4	2
979	Soluble PD-L1 as an early marker of progressive disease on nivolumab. <b>2022</b> , 10,		3
978	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.. <i>BJUI Compass</i> , <b>2022</b> , 3, 169-172	0.9	1
977	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2142046	10.4	1
976	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 569-569	2.2	
975	Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (trCC): Results from an international multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 343-343	2.2	0
974	Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 381-381	2.2	
973	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 317-317	2.2	0
972	Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 323-323	2.2	0
971	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 308-308	2.2	0
970	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 334-334	2.2	1
969	Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 390-390	2.2	
968	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 352-352	2.2	2
967	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100448	3.6	1

966	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 310-310	2.2	
965	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac037	1	0
964	TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS405-TPS405	2.2	1
963	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 281-281	2.2	
962	Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 290-290	2.2	7
961	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 549-549	2.2	
960	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e224304	10.4	4
959	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101806	2.2	1
958	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	2
957	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology</i> , <b>The</b> , <b>2022</b> ,	21.7	6
956	COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO CoCARE). <i>ESMO Open</i> , <b>2022</b> , 100499	6	1
955	Patient-reported outcomes: what really matters to patients? - Authors' reply.. <i>Lancet Oncology</i> , <b>The</b> , <b>2022</b> , 23, e199	21.7	
954	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 158-168	7.5	
953	Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
952	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , <b>2021</b> , 81, 266-266	10.2	4
951	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , <b>2021</b> , 1-6	3.2	
950	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
949	The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.. <i>ESMO Open</i> , <b>2021</b> , 7, 100339	6	3

948	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2134330	10.4	8
947	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.. <i>Lancet Oncology</i> , <b>2021</b> ,	21.7	8
946	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	6
945	Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. <i>European Journal of Medical Genetics</i> , <b>2021</b> , 64, 104359	2.6	1
944	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury.. <i>Kidney360</i> , <b>2021</b> , 2, 205-214	1.8	1
943	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , <b>2021</b> , 79, 334-338	10.2	11
942	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 829-841	59.2	280
941	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , <b>2021</b> , 27, 601-615	50.5	976
940	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <i>Oncologist</i> , <b>2021</b> , 26, e905-e906	5.7	3
939	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. <i>JAMA Oncology</i> , <b>2021</b> , 7, 458-460	13.4	61
938	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , <b>2021</b> , 145, 1-10	7.5	5
937	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC <b>2021</b> , 9,		8
936	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 313-319	19.4	59
935	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1289-1300	59.2	263
934	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e92-e99	3.3	5
933	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , <b>2021</b> , 26, 560-e1103	5.7	1
932	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1330-1335	24.4	1
931	Inhibition of hypoxia-inducible factor-2 $\beta$ n renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. <i>Nature Medicine</i> , <b>2021</b> , 27, 802-805	50.5	48

930	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 455-463	3.7	4
929	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4592-TPS4592 <sup>2.2</sup>	2.2	0
928	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4596-TPS4596	2.2	1
927	Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4548-4548	2.2	1
926	Improving tumor mutational burden calibration in non-European patients.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1559-1559	2.2	
925	Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4529-4529	2.2	
924	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 649-661.e5	24.3	54
923	Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4547-4547	2.2	
922	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 10536-10536	2.2	
921	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4554-4554	2.2	0
920	The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4552-4552	2.2	
919	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4547-4547 <sup>2.2</sup>	2.2	
918	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. <i>European Urology Oncology</i> , <b>2021</b> , 4, 893-893	6.7	5
917	A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4594-TPS4594	2.2	2
916	Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4578-4578	2.2	1
915	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , <b>2021</b> , 79, 665-673	10.2	1
914	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2021</b> , 7, 773-775	13.4	6
913	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4583-4583	2.2	

912	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4561-4561	2.2	3
911	Automated identification of immune related adverse events in oncology patients using machine learning.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1551-1551	2.2	
910	Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4514-4514	2.2	1
909	A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4593-TPS4593	2.2	
908	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 632-648.e8	24.3	42
907	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. <i>ESMO Open</i> , <b>2021</b> , 6, 100101	6	4
906	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , <b>2021</b> , 32, 787-800	10.3	85
905	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4807-4813	12.9	3
904	Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4025-4035	12.9	6
903	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 820-826	3.6	6
902	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1455-1462	7.5	4
901	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1371-1380	12.9	18
900	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , <b>2021</b> , 127, 840-849	6.4	14
899	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 130.e17-130.e24	2.8	1
898	Dissecting the immunogenomic biology of cancer for biomarker development. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 133-134	19.4	2
897	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , <b>2021</b> , 26, 182-e361	5.7	9
896	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 78-86	12.9	60
895	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , <b>2021</b> , 4, 102-111	6.7	15



894	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2087-2099	12.9	3
893	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	8
892	A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1019-1027	12.7	4
891	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2021869	10.4	23
890	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 808	17.4	26
889	Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 310-310	2.2	5
888	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 472-472	2.2	1
887	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 354-354	2.2	
886	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, 1-11	7.1	2
885	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. <i>Cell Reports</i> , <b>2021</b> , 34, 108926	10.6	3
884	B2B: Kidney Cancer Summary. <i>Société Internationale Dfurologie Journal</i> , <b>2021</b> , 2, S19-S28	0.1	
883	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , <b>2021</b> , 39, 895-896	4.3	5
882	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 287	59.2	2
881	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 115-125	7.5	5
880	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	47
879	Metabolic reprogramming in renal cancer: Events of a metabolic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2021</b> , 1876, 188559	11.2	6
878	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 912-920	5.2	
877	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 683-694	59.2	73

876	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. <i>Cancer Cell</i> , <b>2021</b> , 39, 1042-1044	24.3	4
875	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 904	4.8	3
874	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 108, 106481	2.3	1
873	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2926-2937	2.2	10
872	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3725-3736	2.2	13
871	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 108, 106482	2.3	8
870	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 166, 103463	7	1
869	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. <i>Lung Cancer</i> , <b>2021</b> , 160, 78-83	5.9	1
868	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e306-e312	3.3	2
867	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 50-58	7.5	1
866	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , <b>2021</b> , 258-259, 61-68	2.3	0
865	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , <b>2021</b> , 10, 1212-1221	4.8	4
864	Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 199-214	19.4	44
863	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset.. <i>Nature Communications</i> , <b>2021</b> , 12, 7304	17.4	2
862	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
861	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
860	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	5
859	LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. <i>Annals of Oncology</i> , <b>2020</b> , 31, S1201-S1202	10.3	16



858	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , <b>2020</b> , 31, S1202-S1203	10.3	73
857	709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. <i>Annals of Oncology</i> , <b>2020</b> , 31, S558	10.3	8
856	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , <b>2020</b> , 38, 761-766	24.3	12
855	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e598-e609	3.3	4
854	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201839	10.4	17
853	IL-8 and cancer prognosis on immunotherapy. <i>Nature Medicine</i> , <b>2020</b> , 26, 650-651	50.5	32
852	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1030-1039	10.3	144
851	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study <b>2020</b> , 8,		6
850	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , <b>2020</b> , 395, 1907-1918	10.3	880
849	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1807-1814	4.3	2
848	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1606-1610	13.4	36
847	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1247-1255	13.4	51
846	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 909-918	50.5	155
845	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , <b>2020</b> , 26, 1041-1043	50.5	72
844	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 203-210	7.5	28
843	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , <b>2020</b> , 111, 907-923	6.9	19
842	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 293-306	3.7	2
841	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , <b>2020</b> , 3, 530-539	6.7	14

840	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 118-122	7.5	14
839	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1366-1373	8.1	21
838	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , <b>2020</b> , 37, 738-741	24.3	29
837	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , <b>2020</b> , 78, 615-623	10.2	19
836	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors <b>2020</b> , 8,		8
835	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 1075-1084	12.5	21
834	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-10	7.1	10
833	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5010-5010	2.2	2
832	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5063-5063	2.2	3
831	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19321-e19321	2.2	3
830	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 608-608	2.2	5
829	Phase I/II study of the oral HIF-2 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 611-611	2.2	20
828	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 617-617	2.2	19
827	Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 690-690	2.2	2
826	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 715-715	2.2	2
825	Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 728-728	2.2	2
824	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 684-684	2.2	2
823	Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 698-698		

822	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 740-740	2.2	1
821	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1160-1170	7.3	59
820	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5070-5070	2.2	
819	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5046-5046	2.2	
818	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5077-5077	2.2	0
817	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , <b>2020</b> , 38, 629-646	24.3	92
816	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , <b>2020</b> , 204, 1173-1179	2.5	20
815	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 690-696	6.1	7
814	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 63-70	2.2	64
813	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2020</b> , 4, 29-39	0.6	1
812	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2020</b> , 126, 1-10	7.5	13
811	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , <b>2020</b> , 3, 47-56	6.7	12
810	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e350-e359	3.3	1
809	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 555-563	8.7	28
808	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 709-718	8.1	17
807	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 133-141	13.4	5
806	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 410-418	6.2	9
805	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 40-53	24.4	98

804	696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. <i>Annals of Oncology</i> , <b>2020</b> , 31, S1159	10.3	56
803	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2020</b> , 26, 464-470	2.2	5
802	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , <b>2020</b> , 126, 5311-5318	6.4	8
801	Targeting the HIF2-VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 1519-1530	50.5	95
800	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 735.e9-735.e15	2.8	1
799	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. <i>Nature Genetics</i> , <b>2020</b> , 52, 790-799	36.3	62
798	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial <b>2020</b> , 8,		68
797	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , <b>2020</b> , 126, 4156-4167 <sup>66</sup>	6.4	66
796	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , <b>2020</b> , 5, e001079 <sup>6</sup>		109
795	Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 368-374	8	6
794	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma <b>2020</b> , 8,		8
793	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> , <b>2020</b> , 38, 769-770	24.3	23
792	Rethinking Clinical Trials Reform During the COVID-19 Pandemic. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1327-1329	13.4	22
791	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 1248-1257	3.7	22
790	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1514-1527	24.4	80
789	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1320-1335	10.3	121
788	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4240-4248	2.2	27
787	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. <i>Annals of Oncology</i> , <b>2020</b> , 31, S559-S560	10.3	12

786	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , <b>2020</b> , 26, 1733-1741	50.5	85
785	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5598-5608 <sup>12-9</sup>		3
784	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 81-87	6.2	16
783	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , <b>2020</b> , 6, 37-40	5.1	3
782	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , <b>2020</b> , 3, 372-381	6.7	35
781	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , <b>2020</b> , 126, 73-82	5.6	7
780	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma <b>2020</b> , 8,		35
779	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , <b>2019</b> , 76, 861-867	10.2	39
778	Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1631-1633	13.4	89
777	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , <b>2019</b> , 10, 4346	17.4	89
776	The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 443-450.e1	3.3	3
775	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2174-2184	12.9	47
774	Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz003	4.6	5
773	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , <b>2019</b> , 15, 929-941	3.6	23
772	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5202-5211	12.9	14
771	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2404-2415	40	490
770	Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Current Oncology</i> , <b>2019</b> , 26, e175-e179	2.8	13
769	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. <i>Annals of Oncology</i> , <b>2019</b> , 30, 970-976	10.3	158



768	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 593-599	6.2	5
767	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. <i>Nature Communications</i> , <b>2019</b> , 10, 1617	17.4	218
766	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1103-1115	59.2	1069
765	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended Follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1370-1385	21.7	343
764	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , <b>2019</b> , 15, 1683-1695	3.6	19
763	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , <b>2019</b> , 24, 1497-1501	5.7	11
762	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e1060-e1068	3.3	6
761	Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. <i>Circulation</i> , <b>2019</b> , 140, 80-91	16.7	153
760	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , <b>2019</b> , 27, 1589-1598	5.3	15
759	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , <b>2019</b> , 76, 852-860	10.2	4
758	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma <b>2019</b> , 7, 289		9
757	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6080-6088	12.9	33
756	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 101-101	2.2	59
755	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 103-103	2.2	4
754	Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1528-1528	2.2	2
753	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4513-4513	2.2	49
752	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4514-4514	2.2	5
751	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4515-4515	2.2	2



750	Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4518-4518	2.2	8
749	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4568-4568	2.2	4
748	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4583-4583	2.2	8
747	PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4596-TPS4596	2.2	4
746	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4597-TPS4597	2.2	3
745	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 435-435	2.2	6
744	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 544-544	2.2	11
743	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 548-548	2.2	19
742	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 550-550	2.2	2
741	Results from a phase I expansion cohort of the first-in-class oral HIF-2 $\beta$ inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 558-558	2.2	9
740	Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 566-566	2.2	5
739	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 584-584	2.2	4
738	Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 652-652	2.2	3
737	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 653-653	2.2	3
736	CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS682-TPS682	2.2	4
735	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS684-TPS684	2.2	4
734	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 1278-1285	7.3	118
733	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 1049-1058	7.3	14

732	Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 66-66	2.2	
731	Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 664-664	2.2	
730	Hyperprogressive disease on immune checkpoint therapy in advanced solid malignancies: A systematic review.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 154-154	2.2	
729	Germline alterations in urothelial carcinoma (UC) patients with family history of UC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 474-474	2.2	
728	Cell-free DNA analysis in renal cell carcinoma: Comparison with tumor sequencing and correlation with response to therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 655-655	2.2	
727	Genomic profiling of variant urinary tract tumor histologies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 450-450		
726	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 454-454	2.2	
725	Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4571-4571	2.2	
724	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3052-3052	2.2	0
723	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4582-4582	2.2	
722	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4578-4578	2.2	
721	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , <b>2019</b> , 21, e12044	7.6	
720	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4577-4577	2.2	1
719	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , <b>2019</b> , 201, 735-741	2.5	16
718	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , <b>2019</b> , 201, 728-734	2.5	4
717	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 581-590	21.7	81
716	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 425-435.e4	3.3	9
715	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , <b>2019</b> , 24, 202-210	5.7	14

714	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. <i>Kidney Cancer</i> , <b>2019</b> , 3, 241-251	0.6	1
713	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , <b>2019</b> , 2, 643-648	6.7	19
712	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 65-71	3.3	6
711	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 125-136	6.2	29
710	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2458-2470	12.9	52
709	The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002724	11.6	38
708	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 297-305	3.1	17
707	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 552-555 <sup>10.2</sup>	10.2	29
706	Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. <i>Oncogenesis</i> , <b>2019</b> , 8, 7	6.6	32
705	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , <b>2019</b> , 125, 1319-1329	6.4	6
704	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 35-41	10.2	12
703	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , <b>2019</b> , 75, 100-110	10.2	111
702	Radiogenomics in renal cell carcinoma. <i>Abdominal Radiology</i> , <b>2019</b> , 44, 1990-1998	3	24
701	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , <b>2019</b> , 5, 474-481	5.1	27
700	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 451-460	21.7	168
699	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 74, 146-154	10.2	50
698	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1238-1242	8.7	25
697	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , <b>2018</b> , 200, 573-581	2.5	19

696	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
695	The Immune Landscape of Cancer. <i>Immunity</i> , <b>2018</b> , 48, 812-830.e14	32.3	1754
694	Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. <i>Thyroid</i> , <b>2018</b> , 28, 437-444	6.2	19
693	Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. <i>Thyroid</i> , <b>2018</b> , 28, 445-453	6.2	20
692	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 238.e7-238.e17	2.8	11
691	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , <b>2018</b> , 73, e96-e97	10.2	
690	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , <b>2018</b> , 199, 1417-1425	2.5	52
689	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 405-415	21.7	236
688	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 402-408	12.5	42
687	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1805-1815	12.9	38
686	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e327-e333	3.3	7
685	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 88.e1-88.e9	2.8	35
684	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. <i>Cancer</i> , <b>2018</b> , 124, 925-933	6.4	21
683	Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 386-391	10.3	13
682	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , <b>2018</b> , 359, 801-806	33.3	562
681	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e961-e967	3.3	12
680	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , <b>2018</b> , 94, 115-125	7.5	179
679	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1277-1290	59.2	2064

678	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 517-523	2.4	8
677	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , <b>2018</b> , 73, 262-270	10.2	18
676	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , <b>2018</b> , 4, 225-229	13.4	42
675	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , <b>2018</b> , 73, 452-461	10.2	29
674	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , <b>2018</b> , 124, 55-64	6.4	26
673	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. <i>European Urology</i> , <b>2018</b> , 74, e139-e140	10.2	9
672	Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma <b>2018</b> , 6, 5		129
671	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 758-765	12.5	66
670	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , <b>2018</b> , 50, 1271-1281	36.3	249
669	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). <i>Kidney Cancer</i> , <b>2018</b> , 2, 31-36	0.6	6
668	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , <b>2018</b> , 24, 749-757	50.5	558
667	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1767-1774	4	9
666	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1439-1445	3.6	23
665	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , <b>2018</b> , 1, 83-90	6.7	34
664	Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4516-4516	2.2	3
663	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4518-4518	2.2	15
662	Pembrolizumab (pembro) versus investigator choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4521-4521	2.2	5
661	Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4556-4556	2.2	3



660	ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18690-e18690	2.2	1
659	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4598-TPS4598	2.2	22
658	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4599-TPS4599	2.2	11
657	Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4600-TPS4600	2.2	2
656	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS42-TPS42	2.2	4
655	Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 230-230	2.2	1
654	The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 279-279	2.2	1
653	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 410-410	2.2	16
652	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 413-413	2.2	9
651	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 451-451	2.2	1
650	Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 453-453	2.2	2
649	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 579-579	2.2	10
648	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 581-581	2.2	3
647	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 582-582	2.2	5
646	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 607-607	2.2	9
645	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 615-615	2.2	2
644	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 619-619	2.2	2
643	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 626-626	2.2	0



642	Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 639-639	2.2	2
641	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 643-643	2.2	1
640	Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 645-645	2.2	1
639	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS706-TPS706	2.2	7
638	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS710-TPS710	2.2	1
637	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS712-TPS712	2.2	4
636	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 679-679	2.2	
635	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 78-78	2.2	
634	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 634-634	2.2	1
633	Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 23-23	2.2	
632	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 667-667	2.2	
631	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 465-465	2.2	
630	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 492-492	2.2	
629	Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 59-59	2.2	
628	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 629-629	2.2	
627	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4539-4539	2.2	
626	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4597-TPS4597	2.2	
625	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17041-e17041	2.2	

624	Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17027-e17027	2.2	
623	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3036-3036	2.2	
622	Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16554-e16554	2.2	
621	Comprehensive genomic characterization of urothelial carcinomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4527-4527	2.2	
620	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , <b>2018</b> , 73, 71-78	10.2	54
619	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology</i> , <b>2018</b> , 19, 5-7	21.7	2
618	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> <b>2018</b> ;73:262-70. <i>European Urology</i> , <b>2018</b> , 73, e100-e101	10.2	1
617	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 907-910	5.3	37
616	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , <b>2018</b> , 73, 445-451	10.2	27
615	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , <b>2018</b> , 73, 374-382	10.2	42
614	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 $\alpha$ Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 867-874	2.2	198
613	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 757-764	2.2	33
612	Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. <i>Journal of Global Oncology</i> , <b>2018</b> , 4, 1-8	2.6	7
611	Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. <i>Journal of Global Oncology</i> , <b>2018</b> , 4, 1-14	2.6	2
610	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii3-15	10.3	2
609	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 765-772	2.2	78
608	Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018792531	2.2	31
607	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018790253	2.2	41

606	Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2018</b> , 2, 37-46	0.6	2
605	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1579-1587	2.2	68
604	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii308	10.3	2
603	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	1
602	Sequential Response to Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With Fusion-Positive Metastatic Urothelial Carcinoma. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	
601	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1688-1698	21.7	70
600	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders <b>2018</b> , 6, 159		29
599	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 400.e15-400.e22 <sup>1</sup>	2.8	22 <sup>1</sup>
598	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007679	6	8
597	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , <b>2018</b> , 124, 3677-3683	6.4	38
596	Use of Preventive Health Services Among Cancer Survivors in the U.S. <i>American Journal of Preventive Medicine</i> , <b>2018</b> , 55, 830-838	6.1	6
595	Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). <i>Annals of Oncology</i> , <b>2018</b> , 29, viii311	10.3	6
594	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 707-712	8.7	18
593	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 663-669	8.7	48
592	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1434-1441	8.7	17
591	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , <b>2018</b> , 74, 611-620	10.2	49
590	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4081-4088	12.9	17
589	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e317-e326	21.7	23

588	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4399-4406	12.9	23
587	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 341-348	3.3	4
586	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1176-1178	8.7	28
585	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , <b>2017</b> , 71, 204-209	10.2	52
584	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 563-569.e3	3.3	7
583	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 53, 79-97	14.4	64
582	Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8. <i>European Urology</i> , <b>2017</b> , 71, e177-e178	10.2	
581	Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 82-84	19.4	4
580	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 852-860	2.2	79
579	Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 354-366	39.6	641
578	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. <i>Current Urology Reports</i> , <b>2017</b> , 18, 15	2.9	31
577	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , <b>2017</b> , 22, 286-292	5.7	44
576	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 403-410.e2	3.3	12
575	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1015-1026	59.2	1788
574	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1249-1252	13.4	84
573	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 312-318	12.5	259
572	Risk Assessment in Small Renal Masses: A Review Article. <i>Urologic Clinics of North America</i> , <b>2017</b> , 44, 189-202	2.9	3
571	Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 652-660.e1	3.3	21

570	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , <b>2017</b> , 72, 368-376	10.2	148
569	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , <b>2017</b> , 72, 483-487	10.2	65
568	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , <b>2017</b> , 6, 902-909	10.2	28
567	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , <b>2017</b> , 72, 557-564	10.2	81
566	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , <b>2017</b> , 198, 817-823	2.5	21
565	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. <i>European Urology</i> , <b>2017</b> , 71, 714-718	10.2	25
564	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1098-1104	10.3	29
563	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , <b>2017</b> , 31, 820-832	10.3	286
562	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , <b>2017</b> , 8, 15724	17.4	50
561	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , <b>2017</b> , 198, 1061-1068	2.5	26
560	Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. <i>European Urology</i> , <b>2017</b> , 72, 171-174	10.2	28
559	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 338-343	4	8
558	Uncommon Tumors of the Kidney <b>2017</b> , 19-40		0
557	Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 396-402	3.3	3
556	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e1089-e1094	3.3	3
555	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series <b>2017</b> , 5, 66		27
554	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , <b>2017</b> , 1, 41-47	0.6	9
553	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1859-1860	2.2	1



552	Reply to C. Buttiglieri et al and B. Biswas et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1266-1267	2.2	
551	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2993-3001	2.2	112
550	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3916-3923	2.2	204
549	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , <b>2017</b> , 8, 84572-84578	3.3	47
548	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	1
547	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9
546	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 804-834	7.3	320
545	In Reply. <i>Oncologist</i> , <b>2017</b> , 22, 1561	5.7	
544	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , <b>2017</b> , 72, 974-983	10.2	27
543	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE Military Database. <i>Journal of Urology</i> , <b>2017</b> , 198, 1295-1300	2.5	6
542	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , <b>2017</b> , 123, 4346-4355	6.4	85
541	MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA. <i>Journal of Urology</i> , <b>2017</b> , 197,	2.5	1
540	Pan-urologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , <b>2017</b> , 8, 199	17.4	35
539	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , <b>2017</b> , 72, 747-754	10.2	27
538	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 120, 120-126	7	14
537	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 724-732	3.3	24
536	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , <b>2017</b> , 71, 970-978	10.2	12
535	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 221-229	3.3	15



534	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 591-597	2.2	434
533	Immunotherapy in the Elderly. <i>European Urology Focus</i> , <b>2017</b> , 3, 403-412	5.1	12
532	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial. <i>Annals of Oncology</i> , <b>2017</b> , 28, v623	10.3	3
531	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a Homozygous Deletion.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-5	3.6	8
530	Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3016-3016	2.2	4
529	Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3036-3036	2.2	13
528	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4501-4501	2.2	14
527	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4504-4504	2.2	27
526	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4505-4505	2.2	45
525	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4507-4507	2.2	21
524	Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4517-4517	2.2	3
523	Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4520-4520	2.2	20
522	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4530-4530	2.2	5
521	Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4572-4572	2.2	1
520	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4573-4573	2.2	1
519	Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4579-4579	2.2	2
518	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4582-4582	2.2	0
517	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4585-4585	2.2	1

516	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4594-TPS4594	2.2	12
515	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4595-TPS4595	2.2	3
514	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4596-TPS4596	2.2	7
513	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 346-346	2.2	1
512	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 431-431	2.2	52
511	A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 436-436	2.2	6
510	Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 482-482	2.2	9
509	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , <b>2017</b> , 8, 103428-103436	3.3	13
508	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4570-4570	2.2	
507	Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4583-4583	2.2	
506	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16065-e16065	2.2	
505	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4578-4578	2.2	1
504	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11546-11546	2.2	1
503	Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4580-4580	2.2	
502	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16012-e16012	2.2	
501	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , <b>2016</b> , 117, E20-3.6	3.6	19
500	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 820-822	12.5	44
499	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , <b>2016</b> , 15, 695-700	2.4	10

498	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , <b>2016</b> , 122, 3371-3377	6.4	17
497	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , <b>2016</b> , 17, 231	18.3	391
496	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , <b>2016</b> , 6, 27702	4.9	38
495	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 820-4	7.3	26
494	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 421-8	7.3	9
493	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 917-927	21.7	580
492	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2016</b> , 14, 2476-89	10.6	228
491	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3267-75	2.2	139
490	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , <b>2016</b> , 48, 725-32	36.3	193
489	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. <i>Preventive Medicine</i> , <b>2016</b> , 89, 140-145	4.3	38
488	Statins and survival outcomes in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2016</b> , 52, 155-62	7.5	29
487	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , <b>2016</b> , 196, 1090-5	2.5	29
486	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3529-3536	2.2	47
485	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 12-9	8.7	7
484	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e299-305	3.3	9
483	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. <i>JAMA Oncology</i> , <b>2016</b> , 2, 543-5	13.4	5
482	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 57.e15-22	2.8	14
481	Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 12-7	12.5	42

480	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , <b>2016</b> , 69, 866-74	10.2	199
479	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , <b>2016</b> , 2, 204-209	5.1	30
478	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. <i>Journal of Urology</i> , <b>2016</b> , 195, 913-8	2.5	20
477	The impact of Medicare eligibility on cancer screening behaviors. <i>Preventive Medicine</i> , <b>2016</b> , 85, 47-52	4.3	14
476	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2445-2452	12.9	150
475	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 10\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , <b>2016</b> , 87, 125-32	1.6	14
474	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 352-9	3.3	21
473	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , <b>2016</b> , 70, 358-64	10.2	112
472	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 2008-16	40	374
471	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. <i>JAMA Oncology</i> , <b>2016</b> , 2, 500-7	13.4	67
470	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , <b>2016</b> , 70, 516-21	10.2	61
469	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , <b>2016</b> , 69, 634-641	10.2	47
468	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753
467	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , <b>2016</b> , 195, 277-82	2.5	40
466	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , <b>2016</b> , 118, 95-101	5.6	36
465	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 85-93	13.4	61
464	A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2 $\alpha$ inhibitor, in patients with advanced clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2506-2506	2.2	4
463	Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2565-2565	2.2	2

462	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3013-3013	2.2	4
461	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4506-4506	2.2	1
460	Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4507-4507	2.2	25
459	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4509-4509 <sup>2</sup>	2.2	9
458	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4524-4524	2.2	3
457	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4540-4540 <sup>2</sup>	2.2	2
456	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4557-4557	2.2	3
455	Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4558-4558	2.2	6
454	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4570-4570	2.2	1
453	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23221-e23221	2.2	1
452	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4576-TPS4576	2.2	8
451	Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4580-TPS4580	2.2	8
450	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 499-499	2.2	7
449	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 501-501	2.2	1
448	Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 514-514	2.2	8
447	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 545-545	2.2	8
446	Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 570-570	2.2	2
445	Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 73-73	2.2	2



444	Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. <i>Oncotarget</i> , <b>2016</b> , 7, 29901-15	3.3	39
443	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 552-552	2.2	0
442	Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 363-363	2.2	
441	Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 588-588	2.2	
440	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 54-54	2.2	
439	Assessment of metastasectomy complications in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 619-619	2.2	
438	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 450-450	2.2	
437	Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 431-431	2.2	
436	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 386-386	2.2	
435	Characterization of mutational load in patients with advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 460-460	2.2	
434	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 616-616	2.2	
433	The impact of weight change during treatment with targeted therapy in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 557-557	2.2	
432	Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 620-620	2.2	
431	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 534-534	2.2	
430	Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 531-531	2.2	
429	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 33-33	2.2	
428	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 442-442	2.2	
427	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 304-304	2.2	

426	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 503-503	2.2	
425	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4554-4554	2.2	
424	Virtual consults: A paradigm shift for second opinions in oncology care.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18049-e18049	2.2	
423	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4510-4510	2.2	
422	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4573-4573	2.2	
421	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4535-4535	2.2	
420	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3068-3068	2.2	
419	Fixed tissue CHIP-seq (FIT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4541-4541	2.2	
418	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2016</b> , 39, 497-506	2.7	11
417	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , <b>2016</b> , 122, 411-9	6.4	23
416	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , <b>2016</b> , 118, 279-85	5.6	9
415	Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 556-7	9.5	63
414	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , <b>2016</b> , 118, 286-97	5.6	30
413	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , <b>2016</b> , 122, 402-10	6.4	13
412	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , <b>2016</b> , 122, 2389-98	6.4	9
411	CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi566	10.3	8
410	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 304-313.e6	3.3	10
409	Kidney cancer: Recurrence in renal cell carcinoma: the work is not done. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 246-7	5.5	7

408	Data on Medicare eligibility and cancer screening utilization. <i>Data in Brief</i> , <b>2016</b> , 7, 679-81	1.2	4
407	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , <b>2016</b> , 2, 633-639	5.1	9
406	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 233.e7-15	2.8	24
405	PD04-05 TRENDS OF METASTASECTOMY FOR METASTATIC RENAL CELL CARCINOMA AND THEIR IMPACT ON OVERALL SURVIVAL. <i>Journal of Urology</i> , <b>2016</b> , 195,	2.5	1
404	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 494-498	3.3	1
403	Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 889-90	59.2	21
402	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1905-12	2.2	92
401	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , <b>2016</b> , 29, 723-736	3.3	324
400	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma <b>2016</b> , 4, 26		8
399	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5461-5471	12.9	158
398	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3655-3663	2.2	111
397	Determinants of cancer screening in Asian-Americans. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 989-98	2.8	19
396	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 102-8	7.5	51
395	RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 130-7	6.6	32
394	Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e79-85	3.3	59
393	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 251-63	7	7
392	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 330.e19-25	2.8	12
391	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1190-8	8.7	27

390	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 525-30.e1-3	3.3	13
389	Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. <i>Cancer</i> , <b>2015</b> , 121, 311-9	6.4	129
388	Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv054	9.7	51
387	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , <b>2015</b> , 194, 343-9	2.5	88
386	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 136-45	7	25
385	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2013-20	2.2	337
384	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 228-37	7	77
383	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 293-300	21.7	229
382	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2471-9	12.9	88
381	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 426-35	21.7	209
380	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>European Urology</i> , <b>2015</b> , 67, 952-8	10.2	53
379	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1071-7	12.9	173
378	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1814-23	59.2	762
377	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1803-13	59.2	3725
376	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
375	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 538-45	2.8	9
374	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 250-6	3.3	5
373	RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>American Journal of Roentgenology</i> , <b>2015</b> , 204, W282-8	5.4	16

372	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3431-8	2.2	44
371	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 496.e11-6	2.8	31
370	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 503.e7-15	2.8	7
369	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 828-35	4	32
368	Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. <i>European Urology</i> , <b>2015</b> , 68, 506-15	10.2	27
367	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2580-6	7.5	69
366	Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. <i>Surgical Pathology Clinics</i> , <b>2015</b> , 8, 657-62	3.9	7
365	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 150-5	3.3	9
364	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 504.e9-17	2.8	19
363	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 2077-9	27.4	84
362	Future directions and targeted therapies in bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2015</b> , 29, 361-76, x	3.1	21
361	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , <b>2015</b> , 116, 358-65	5.6	51
360	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 17.e9-17.e18	2.8	20
359	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 18.e7-18.e13	2.8	41
358	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. <i>European Urology</i> , <b>2015</b> , 67, 100-110	10.2	106
357	Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 71-9	3.3	9
356	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8	10.3	22
355	HER2 as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , <b>2015</b> , 4, 844-52	4.8	31



354	Kidney cancer, version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 151-9	7.3	166
353	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1131-8	7.3	30
352	The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 1168-70	7.3	2
351	Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 61-8	7.3	49
350	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 772-99	7.3	87
349	An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. <i>BJU International</i> , <b>2015</b> , 116, 911-9	5.6	7
348	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). <i>Prostate</i> , <b>2015</b> , 75, 1677-81	4.2	10
347	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 3435-43	6.4	53
346	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab <b>2015</b> , 3,		1
345	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139267	3.7	28
344	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study <b>2015</b> , 3, 3		63
343	Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 609-16	2.4	14
342	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 68, 32-9	10.2	35
341	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1158-64	12.5	205
340	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 257-76	7	27
339	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 185-92	3.3	2
338	Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. <i>Urology</i> , <b>2015</b> , 85, 343-9	1.6	14
337	Incidence and determinants of 1-month mortality after cancer-directed surgery. <i>Annals of Oncology</i> , <b>2015</b> , 26, 399-406	10.3	12

336	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 812-817	10.3	202
335	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 8110-20	5.4	96
334	QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 296-305	8.7	92
333	Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2503-2503	2.2	13
332	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3009-3009	2.2	12
331	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4500-4500	2.2	10
330	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4508-4508	2.2	2
329	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4519-4519	2.2	1
328	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4559-4559	2.2	2
327	Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4564-4564	2.2	1
326	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4571-TPS4571	2.2	6
325	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 311-311	2.2	1
324	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 364-364	2.2	1
323	Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 404-404	2.2	1
322	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 405-405	2.2	1
321	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 408-408	2.2	2
320	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 422-422	2.2	1
319	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 426-426	2.2	7

318	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 430-430	2.2	2
317	Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 433-433	2.2	1
316	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 464-464	2.2	1
315	cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 487-487	2.2	4
314	Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 95-95	2.2	2
313	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124711	3.7	15
312	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma <b>2015</b> , 555-567		
311	The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 414-414	2.2	
310	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 32-32	2.2	
309	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 365-365	2.2	
308	Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 435-435	2.2	
307	Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 456-456	2.2	2
306	Genomic landscape of high-grade T1 micropapillary bladder tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 299-299	2.2	
305	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum-based chemotherapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 351-351	2.2	
304	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 406-406	2.2	
303	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 369-369	2.2	2
302	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 34-34	2.2	
301	Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4530-4530	2.2	

300	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4527-4527 <sup>2,2</sup>		
299	Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15518-e15518	2.2	
298	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15520-e15520 <sup>2,2</sup>		
297	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4520-4520	2.2	
296	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15578-e15578	2.2	0
295	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4560-4560	2.2	
294	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15583-e15583	2.2	
293	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15519-e15519	2.2	
292	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4521-4521	2.2	1
291	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17528-e17528	2.2	
290	Non-clear cell renal cell carcinoma, part 1: histology. <i>Clinical Advances in Hematology and Oncology</i> , <b>2015</b> , 13, 308-13	0.6	8
289	Non-clear cell renal cell carcinoma, part 2: therapy. <i>Clinical Advances in Hematology and Oncology</i> , <b>2015</b> , 13, 383-91	0.6	13
288	Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. <i>European Urology</i> , <b>2014</b> , 66, 1125-32	10.2	21
287	Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. <i>European Urology</i> , <b>2014</b> , 66, 502-9	10.2	56
286	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. <i>European Urology</i> , <b>2014</b> , 65, 577-84	10.2	166
285	ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. <i>European Urology</i> , <b>2014</b> , 66, 77-84	10.2	169
284	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 178-87	4.3	226
283	Precision medicine for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 5-15	2.8	14

282	Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). <i>BJU International</i> , <b>2014</b> , 113, E67-74	5.6	43
281	Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2014</b> , 16, 335	2.1	27
280	Mental health outcomes in elderly men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1333-40	2.8	39
279	Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1419-26	2.2	140
278	Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. <i>Urology</i> , <b>2014</b> , 84, 386-92	1.6	60
277	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , <b>2014</b> , 26, 319-330	24.3	521
276	Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , <b>2014</b> , 66, 704-10	10.2	282
275	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. <i>Cancer Discovery</i> , <b>2014</b> , 4, 546-53	24.4	224
274	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1889-94	2.2	177
273	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 335-40	3.3	7
272	Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e189-95	3.3	37
271	Weight gain on androgen deprivation therapy: which patients are at highest risk?. <i>Urology</i> , <b>2014</b> , 83, 1316-21	6.1	14
270	MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. <i>Journal of Urology</i> , <b>2014</b> , 191,	2.5	1
269	A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>European Urology</i> , <b>2014</b> , 66, 529-41	10.2	181
268	The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , <b>2014</b> , 65, 723-30	10.2	59
267	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e127-31	3.3	20
266	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 130-7	3.3	26
265	Adrenocortical carcinoma: the management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 92, 123-32	7	36



264	Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , <b>2014</b> , 5, 352-8	3.6	17
263	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1285-91	2.8	62
262	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 395-8	3.3	11
261	Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. <i>European Urology</i> , <b>2014</b> , 65, 1086-92	10.2	56
260	Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 384-96	7.5	51
259	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 175-82	7.3	43
258	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 1629-49	7.3	12
257	Identification of ALK gene alterations in urothelial carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e103325	3.7	8
256	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1140-53	24.4	361
255	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1873-83	12.9	38
254	Genomic investigation of etiologic heterogeneity: methodologic challenges. <i>BMC Medical Research Methodology</i> , <b>2014</b> , 14, 138	4.7	11
253	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1917-22	8.7	54
252	Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1433-7	8.7	17
251	The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2014</b> , 17, 273-9	6.2	42
250	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. <i>Annals of Oncology</i> , <b>2014</b> , 25, 149-54	10.3	99
249	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4171-2	2.2	
248	Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. <i>BMJ Open</i> , <b>2014</b> , 4, e003921	3	26
247	A phase I study of cabozantinib (XL184) in patients with renal cell cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1603-8	10.3	115

246	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. <i>Cancer Medicine</i> , <b>2014</b> , 3, 835-44	4.8	63
245	Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. <i>Cancer</i> , <b>2014</b> , 120, 1532-9	6.4	153
244	A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. <i>Cancer</i> , <b>2014</b> , 120, 1647-55	6.4	25
243	Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. <i>Cancer</i> , <b>2014</b> , 120, 711-21	6.4	36
242	PD-L1 expression in nonclear-cell renal cell carcinoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2178-2184	10.3	202
241	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 1132-41	12.5	33
240	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , <b>2014</b> , 113, E137-43	5.6	28
239	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2014</b> , 20, 272-80	2.2	14
238	Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1769-70	59.2	199
237	MET as a target in papillary renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3361-3	12.9	18
236	Cancer-specific outcomes among young adults without health insurance. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2025-30	2.2	97
235	10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. <i>Oncologist</i> , <b>2014</b> , 19, 507-14	5.7	42
234	Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. <i>European Urology</i> , <b>2014</b> , 66, 42-54	10.2	277
233	Refusal of curative radiation therapy and surgery among patients with cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 756-64	4	39
232	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 354-8	3.3	20
231	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 262-9	3.3	8
230	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 190-6	14.4	57
229	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , <b>2014</b> , 9, 195-204	5	16

228	Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4503-4503	2.2	3
227	Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4505-4505	2.2	12
226	Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4510-4510	2.2	2
225	CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4527-4527	2.2	1
224	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4552-4552	2.2	2
223	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4576-4576	2.2	2
222	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4585-4585	2.2	5
221	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5012-5012	2.2	24
220	Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5027-5027	2.2	8
219	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4593-TPS4593	2.2	3
218	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 334-334	2.2	1
217	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 336-336	2.2	1
216	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 353-353	2.2	1
215	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 395-395	2.2	1
214	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 396-396	2.2	7
213	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 398-398	2.2	6
212	Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 416-416	2.2	4
211	PD-L1 expression in non-clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 424-424	2.2	3

210	Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 437-437	2.2	3
209	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 467-467	2.2	12
208	Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 470-470	2.2	3
207	ABO blood group and risk of lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 69-69	2.2	1
206	Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e116101	3.7	17
205	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9639-9639	2.2	
204	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5091-5091	2.2	
203	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4514-4514	2.2	
202	Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15558-e15558	2.2	
201	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e13547-e13547	2.2	
200	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4526-4526	2.2	1
199	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e13502-e13502	2.2	
198	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4570-4570	2.2	
197	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 432-432	2.2	
196	Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 330-330	2.2	
195	Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer patients in an academic setting.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 224-224	2.2	
194	Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 411-411	2.2	
193	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 409-409	2.2	

192	Use of surveillance imaging following treatment of small renal masses. <i>Journal of Urology</i> , <b>2013</b> , 190, 1680-5	2.5	14
191	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , <b>2013</b> , 8, 203-209	5	45
190	Pazopanib versus sunitinib in metastatic renal-cell carcinoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 722-31	59.2	1332
189	Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. <i>BJU International</i> , <b>2013</b> , 112, E273-80	5.6	25
188	Marital status and survival in patients with cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3869-76	2.2	606
187	Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2013</b> , 27, 1261-83, ix	3.1	4
186	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , <b>2013</b> , 119, 2999-3006	6.4	144
185	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2013</b> , 16, 266-70	6.2	1
184	Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 311-5	3.3	50
183	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 141-8	21.7	598
182	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 181-6	2.2	336
181	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 81-7	21.7	46
180	Renal-cell carcinoma: a step closer to a new classification. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 105-7	21.7	7
179	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 495-500	3.3	16
178	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1788-93	2.8	37
177	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 87, 80-9	7	49
176	Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. <i>Urology</i> , <b>2013</b> , 81, 130-4	1.6	19
175	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , <b>2013</b> , 63, 717-23	10.2	88



174	Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. <i>Trends in Cardiovascular Medicine</i> , <b>2013</b> , 23, 104-13	6.9	78
173	Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. <i>Brachytherapy</i> , <b>2013</b> , 12, 415-21	2.4	5
172	Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1466-72	10.3	117
171	Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. <i>Drugs</i> , <b>2013</b> , 73, 1417-30	12.1	30
170	The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 2548-53	8.7	11
169	Comprehensive molecular characterization of clear cell renal cell carcinoma. <i>Nature</i> , <b>2013</b> , 499, 43-9	50.4	2184
168	Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2927-8	10.3	24
167	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1202-12	3.2	36
166	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2013</b> , 19, 316-23	2.2	42
165	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5218-26	12.9	65
164	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2092-7	10.3	27
163	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 2478-84	8.7	26
162	Clinical treatment decisions for advanced renal cell cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 694-7	7.3	12
161	Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4514-4514	2.2	22
160	Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 161-161	2.2	1
159	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 301-301	2.2	2
158	Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 351-351	2.2	5
157	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 394-394	2.2	1

156	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 398-398	2.2	1
155	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 430-430	2.2	1
154	Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 283-283	2.2	
153	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 353-353	2.2	1
152	Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 23-23	2.2	
151	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 276-276	2.2	
150	Metastatic nonclear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 396-396	2.2	
149	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 347-347	2.2	
148	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <i>European Urology</i> , <b>2012</b> , 61, 307-16	10.2	43
147	Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. <i>European Urology</i> , <b>2012</b> , 61, 1239-44	10.2	134
146	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , <b>2012</b> , 118, 365-70	6.4	17
145	Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. <i>Cancer</i> , <b>2012</b> , 118, 797-803	6.4	20
144	BRAF mutations in metanephric adenoma of the kidney. <i>European Urology</i> , <b>2012</b> , 62, 917-22	10.2	76
143	Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 1411-6	4	53
142	Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. <i>Journal of Urology</i> , <b>2012</b> , 187, 2068-73	2.5	18
141	Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2012</b> , 30, 848-55	2.8	9
140	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2012</b> , 30, 900-5	2.8	12
139	Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. <i>Aging Male</i> , <b>2012</b> , 15, 34-41	2.1	17

138	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1009-16	8.7	28
137	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1495-502	7.5	15
136	Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1519-24	7.5	74
135	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , <b>2012</b> , 13, 927-35	21.7	104
134	ABO blood group and risk of renal cell cancer. <i>Cancer Epidemiology</i> , <b>2012</b> , 36, 528-32	2.8	26
133	Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. <i>Journal of Urology</i> , <b>2012</b> , 188, 775-80	2.5	14
132	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. <i>Cancer</i> , <b>2012</b> , 118, 4777-84	6.4	40
131	The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 295-306	6.3	24
130	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4416-26	2.2	152
129	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 871-7	2.2	144
128	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1549-55	10.3	108
127	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1837-40	9.7	27
126	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 507-12	2.2	151
125	Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e264-8	2.2	37
124	Testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 502-35	7.3	64
123	Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4504-4504	2.2	11
122	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4505-4505	2.2	5
121	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4525-4525	2.2	1

120	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4577-4577	2.2	1
119	A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS4686-TPS4686	2.2	1
118	Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 352-352	2.2	2
117	A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 353-353	2.2	3
116	A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 355-355	2.2	6
115	Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 364-364	2.2	12
114	Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 372-372	2.2	6
113	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 387-387	2.2	5
112	The evolving landscape of metastatic renal cell carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 299-302	7.1	8
111	Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer <b>2012</b> , 347-359		
110	Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e15007-e15007	2.2	
109	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e21016-e21016	2.2	
108	Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. <i>Journal of Urology</i> , <b>2011</b> , 185, 439-44	2.5	98
107	Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. <i>Hematology/Oncology Clinics of North America</i> , <b>2011</b> , 25, 853-69	3.1	20
106	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. <i>Journal of Urology</i> , <b>2011</b> , 185, 60-6	2.5	258
105	Recent advances in immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 997-1009	5.4	15
104	Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 645-53	4.1	30
103	Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. <i>Journal of Urology</i> , <b>2011</b> , 185, 116-20	2.5	70

102	Haematologic toxicities associated with the addition of bevacizumab in cancer patients. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1161-74	7.5	35
101	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2706-14	7.5	29
100	Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. <i>Urology</i> , <b>2011</b> , 77, 402-6	1.6	31
99	Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. <i>Urology</i> , <b>2011</b> , 78, 93-8	1.6	79
98	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 756-63	2.8	9
97	NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2011</b> , 9 Suppl 1, S1-29	7.3	41
96	Kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2011</b> , 9, 960-77	7.3	79
95	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. <i>BJU International</i> , <b>2011</b> , 108, 1279-83	5.6	42
94	Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 80, 291-300	7	48
93	Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. <i>European Urology</i> , <b>2011</b> , 59, 856-62	10.2	90
92	ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. <i>European Urology</i> , <b>2011</b> , 60, 684-90	10.2	100
91	Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. <i>Prostate</i> , <b>2011</b> , 71, 1189-97	4.2	41
90	Reply to impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. <i>Cancer</i> , <b>2011</b> , 117, 656-656	6.4	
89	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , <b>2011</b> , 117, 2637-42	6.4	64
88	Utilization and expense of adjuvant cancer therapies following radical prostatectomy. <i>Cancer</i> , <b>2011</b> , 117, 4846-54	6.4	27
87	Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 1318-22	4	9
86	Pazopanib: Clinical development of a potent anti-angiogenic drug. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 77, 163-71	7	111
85	VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. <i>Current Clinical Pharmacology</i> , <b>2011</b> , 6, 164-8	2.5	15



84	New therapies for castrate-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2069-74	5	
83	Congestive heart failure risk in patients with breast cancer treated with bevacizumab. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 632-8	2.2	222
82	Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1404-1412	10.3	110
81	Everolimus- and temsirolimus-associated enteritis: report of three cases. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e404-6	2.2	11
80	Impact of body composition on clinical outcomes in metastatic renal cell cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1484-6	5.7	15
79	Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3450-6	2.2	140
78	Cost implications of the rapid adoption of newer technologies for treating prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1517-24	2.2	240
77	Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 2359-66	27.4	292
76	Prospective evaluation of analgesic use and risk of renal cell cancer. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 1487-93		51
75	Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5443-50	12.9	142
74	Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. <i>Annals of Oncology</i> , <b>2011</b> , 22, 245-7	10.3	10
73	VEGF inhibitors <b>2011</b> , 28-41		
72	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. <i>BJU International</i> , <b>2010</b> , 105, 1247-54	5.6	56
71	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , <b>2010</b> , 106, 772-8	5.6	73
70	Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. <i>BJU International</i> , <b>2010</b> , 106, 979-85	5.6	16
69	$^{11}\text{C}$ -methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. <i>BJU International</i> , <b>2010</b> , 106, 1249-50	5.6	1
68	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2280-5	2.2	346
67	Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e433-5	2.2	12

66	Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1850-5	2.2	268
65	Reply to D.R. Minor. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e620-e620	2.2	
64	Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. <i>Hypertension</i> , <b>2010</b> , 56, 1131-6	8.5	94
63	Updates on novel therapies for metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2010</b> , 2, 209-19	5.4	17
62	Elicitation of health state utilities in metastatic renal cell carcinoma. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 1091-6	2.5	43
61	Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. <i>Urology</i> , <b>2010</b> , 76, 430-4	1.6	72
60	Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?—implications for a risk-adapted follow-up strategy. <i>Urology</i> , <b>2010</b> , 76, 1201-5	1.6	22
59	Risk of bleeding not increased by sorafenib or sunitinib [Authors' reply. <i>Lancet Oncology</i> , <b>2010</b> , 11, 113	21.7	1
58	Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. <i>Cancer</i> , <b>2010</b> , 116, 610-5	6.4	10
57	Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. <i>Cancer</i> , <b>2010</b> , 116, 1887-92	6.4	30
56	Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , <b>2010</b> , 116, 5219-25	6.4	97
55	Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , <b>2010</b> , 116, 5400-6	6.4	106
54	Cancer of the Genitourinary Tract <b>2010</b> , 233-277		
53	Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?. <i>Nature Reviews Clinical Oncology</i> , <b>2009</b> , 6, 679-80	19.4	3
52	Metastatic renal cell carcinoma: A guide to therapy based on current evidence. <i>Urology Annals</i> , <b>2009</b> , 1, 9	1	1
51	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5794-9	2.2	1390
50	Risk of bilateral renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3737-41	2.2	35
49	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , <b>2009</b> , 115, 981-7	6.4	87

48	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>2009</b> , 115, 2327-33	6.4	27
47	Optimizing recent advances in metastatic renal cell carcinoma. <i>Current Oncology Reports</i> , <b>2009</b> , 11, 218-263		9
46	A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E93-4	3.3	23
45	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 2081-90	2.5	16
44	Sunitinib in renal-cell carcinoma: expanded indications. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 740	21.7	4
43	Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 967-74	21.7	219
42	Recent advances in the systemic treatment of metastatic papillary renal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2009</b> , 9, 373-9	3.5	25
41	Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. <i>Journal of Urology</i> , <b>2009</b> , 181, 2470-5; discussion 2475	2.5	21
40	Non-clear cell renal cancer: features and medical management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 659-65	7.3	27
39	NCCN clinical practice guidelines in oncology: kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 618-30	7.3	168
38	NCCN clinical practice guidelines in oncology: testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 672-93	7.3	87
37	An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. <i>BJU International</i> , <b>2008</b> , 101, 712-5	5.6	26
36	Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. <i>Clinical Genitourinary Cancer</i> , <b>2008</b> , 6, 15-20	3.3	6
35	Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. <i>European Urology Supplements</i> , <b>2008</b> , 7, 494-507	0.9	2
34	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. <i>Journal of Urology</i> , <b>2008</b> , 180, 860-5; discussion 865-6	2.5	170
33	Patterns of care for radical prostatectomy in the United States from 2003 to 2005. <i>Journal of Urology</i> , <b>2008</b> , 180, 1969-74	2.5	37
32	A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. <i>Journal of Urology</i> , <b>2008</b> , 179, 906-10; discussion 910	2.5	87
31	Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 444-54		40

30	Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. <i>Future Oncology</i> , <b>2008</b> , 4, 85-92	3.6	19
29	The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 698-9		4
28	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 127-31	2.2	328
27	Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>2008</b> , 113, 1309-14	6.4	29
26	Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. <i>Current Opinion in Investigational Drugs</i> , <b>2008</b> , 9, 658-71		46
25	Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , <b>2007</b> , 110, 543-50	6.4	198
24	Differential expression of caveolin-1 in renal neoplasms. <i>Cancer</i> , <b>2007</b> , 110, 776-82	6.4	20
23	The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. <i>Breast Journal</i> , <b>2007</b> , 13, 130-9	1.2	33
22	Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. <i>Annals of Oncology</i> , <b>2007</b> , 18, 249-55	10.3	42
21	Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. <i>Acta Haematologica</i> , <b>2007</b> , 117, 162-7	2.7	34
20	Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. <i>Journal of Urology</i> , <b>2007</b> , 178, 1901-5	2.5	53
19	Management of clinical stage I nonseminomatous germ cell testicular cancer. <i>Urologic Clinics of North America</i> , <b>2007</b> , 34, 137-48; abstract viii	2.9	25
18	Phenoxodiol: isoflavone analog with antineoplastic activity. <i>Current Oncology Reports</i> , <b>2006</b> , 8, 104-7	6.3	24
17	The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. <i>Seminars in Oncology</i> , <b>2006</b> , 33, 596-606	5.5	32
16	Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>2006</b> , 107, 2609-16	6.4	52
15	Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17, 860-5	10.3	31
14	Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6702-8	12.9	77
13	Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1766-71	10.3	121

12	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1097-104	6.7	206
11	Daptomycin-resistant <i>Enterococcus faecium</i> in a patient with acute myeloid leukemia. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 1215-6	6.4	65
10	Role of aromatase inhibitors in the treatment of breast cancer. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1199-214	3.5	36
9	Evolving role of pegylated interferons in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 823-9	3.5	20
8	Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 959	4.5	7
7	An overview of targeted treatments in cancer. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2121-37	3.5	75
6	Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. <i>American Journal of Medicine</i> , <b>2002</b> , 113, 700-1	2.4	4
5	Why shouldn't we use warfarin alone to treat acute venous thrombosis?. <i>Cleveland Clinic Journal of Medicine</i> , <b>2002</b> , 69, 546-8	2.8	4
4	HIF-2 $\alpha$ drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma		1
3	PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma		3
2	Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma		2
1	Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19		12